Evidence map›Paper›PMID 11986369›Full record

ArticleThe Journal of physiology2002

Adenosine inhibition via A(1) receptor of N-type Ca(2+) current and peptide release from isolated neurohypophysial terminals of the rat.

Gang Wang, Govindan Dayanithi, Edward E Custer, José R Lemos

Abstract read
In one paragraph

Article in The Journal of physiology, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Review
  3. Purinergic signaling pathways in endocrine system.Autonomic neuroscience : basic & clinical · 2015
    Review
  4. Purinergic signalling in endocrine organs.Purinergic signalling · 2014
    Review
  5. Article
  6. Review
  7. Purinergic regulation of hypothalamopituitary functions.Trends in endocrinology and metabolism: TEM · 2009
    Review
  8. Article
  9. NADPH oxidase contributes to angiotensin II signaling in the nucleus tractus solitarius.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2004
    Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Gang WangDepartment of Physiology and Neuroscience Program, University of Massachusetts Medical School, 55 Lake Avenue North, Worcester, MA 01655, USA.
Govindan Dayanithi
Edward E Custer
José R Lemos

Funding

DEPOLARIZATION/SECRETION COUPLING IN NERVE TERMINALSR01NS029470 · NINDS · WORCESTER FOUNDATION FOR BIOMEDICAL RES · PI LEMOS, JOSE R · 1991 to 2012
$4.3M
MECHANISMS OF OPIOID ACTION ON PEPTIDE RELEASER01DA010487 · NIDA · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI LEMOS, JOSE R · 1998 to 2002
$866k
NIDA NIH HHS DA10487NIDA NIH HHS R01 DA010487NINDS NIH HHS NS29470NINDS NIH HHS R01 NS029470
6 · The paper itself

Abstract

Effects of adenosine on voltage-gated Ca(2+) channel currents and on arginine vasopressin (AVP) and oxytocin (OT) release from isolated neurohypophysial (NH) terminals of the rat were investigated using perforated-patch clamp recordings and hormone-specific radioimmunoassays. Adenosine, but not adenosine 5'-triphosphate (ATP), dose-dependently and reversibly inhibited the transient component of the whole-terminal Ba(2+) currents, with an IC(50) of 0.875 microM. Adenosine strongly inhibited, in a dose-dependent manner (IC(50) = 2.67 microM), depolarization-triggered AVP and OT release from isolated NH terminals. Adenosine and the N-type Ca(2+) channel blocker omega-conotoxin GVIA, but not other Ca(2+) channel-type antagonists, inhibited the same transient component of the Ba(2+) current. Other components such as the L-, Q- and R-type channels, however, were insensitive to adenosine. Similarly, only adenosine and omega-conotoxin GVIA were able to inhibit the same component of AVP release. A(1) receptor agonists, but not other purinoceptor-type agonists, inhibited the same transient component of the Ba(2+) current as adenosine. Furthermore, the A(1) receptor antagonist 8-cyclopentyltheophylline (CPT), but not the A(2) receptor antagonist 3, 7-dimethyl-1-propargylxanthine (DMPGX), reversed inhibition of this current component by adenosine. The inhibition of AVP and OT release also appeared to be via the A(1) receptor, since it was reversed by CPT. We therefore conclude that adenosine, acting via A(1) receptors, specifically blocks the terminal N-type Ca(2+) channel thus leading to inhibition of the release of both AVP and OT.

Indexed as

Purinergic P1 Receptor AntagonistsAdenosineAdenosine TriphosphateAnimalsArginine VasopressinBariumCalcium Channels, N-TypeIn Vitro TechniquesKineticsMembrane PotentialsNerve EndingsOxytocinPatch-Clamp TechniquesPituitary Gland, PosteriorPurinergic P1 Receptor AgonistsRats8-cyclopentyl-1,3-dimethylxanthineAdenosineAdenosine TriphosphateArginine VasopressinBariumCalcium Channels, N-TypeOxytocinPurinergic P1 Receptor AgonistsPurinergic P1 Receptor AntagonistsReceptors, Purinergic P1Theophylline

Identifiers

PMID11986369
PMCPMC2290279

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.